Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-052
Antithrombotic Therapy for Flow-Diverting Stents in Cerebral Arteries: 12-Month Follow-up
By Daniel Gitelson, Aleksandr Vasilev, Ekaterina Gitelzon, Alexandr Faibushevich, Alexandr Deneka, Karen Danishan
Presenter
Daniel Gitelson
Authors
Daniel Gitelson1, Aleksandr Vasilev1, Ekaterina Gitelzon2, Alexandr Faibushevich2, Alexandr Deneka3, Karen Danishan1
Affiliation
National Medical Research Center for Hematology, Russian Federation1, RUDN University (Peoples' Friendship University of Russia), Russian Federation2, Fox Chase Cancer Center, USA3
View Study Report
TCTAP A-052
Carotid & Neurovascular Intervention
Antithrombotic Therapy for Flow-Diverting Stents in Cerebral Arteries: 12-Month Follow-up
Daniel Gitelson1, Aleksandr Vasilev1, Ekaterina Gitelzon2, Alexandr Faibushevich2, Alexandr Deneka3, Karen Danishan1
National Medical Research Center for Hematology, Russian Federation1, RUDN University (Peoples' Friendship University of Russia), Russian Federation2, Fox Chase Cancer Center, USA3
Background
Cerebral aneurysms are an extremely dangerous pathology. Subarachnoid hemorrhage or hemorrhage into the brain tissue occurs when the aneurysm ruptures. Mortality in such cases is up to 30%. Morphologically, aneurysms are divided into fusiform and saccular. Flow-diverting stents can treat fusiform and saccular aneurysms with a wide neck by prevention of blood flow in the aneurysm cavity. However, the question of optimal antithrombotic therapy for flow-diverting stents implantation in cerebral arteries remains open. We compared the effectiveness of ticagrelor and clopidogrel as part of dual antiplatelet therapy for flow-diverting stents implantation in cerebral arteries.
Methods
The study included 23 patients with cerebral aneurysms. All patients were randomized into 2 groups. Group I (n=12) included patients taking acetylsalicylic acid 100 mg once a day and ticagrelor 90 mg twice a day orally. Group II (n=11) included patients taking acetylsalicylic acid 100 mg once a day and clopidogrel 75 mg once a day orally. All patients underwent flow-diverting stents (Pipeline Flex, Medtronic, USA) implantation in cerebral arteries. The follow-up period was 12 months.
Results
There were no major adverse cardiovascular events in group I. In group II, during this time, two (18%) transient ischemic attacks occurred in the basin of cerebral arteries with flow-diverting stents.
Conclusion
Tiсagrelor has an advantage in comparison to clopidogrel as part of dual antiplatelet therapy for flow-diverting stents implantation in cerebral arteries.